Empagliflozin for HFrEF — Post Hoc Analysis of EMPEROR-Reduced

Empagliflozin helps, even on the background of other cardiovascular drugs.

Empagliflozin improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF), but how much does background therapy with other medications influence results? In an industry-sponsored, randomized trial (EMPEROR-Reduced) in 3730 patients with HFrEF, empagliflozin (compared with placebo) lowered the primary outcome of first hospitalization for HF or cardiovascular-related death by 25% — from 24.7% to 19.4% (NEJM JW Gen Med Oct 1 2020 and N Engl J Med 2020; 383:1413). Now, in a post hoc analysis, investigators looked at whether these results were influenced by concurrent therapies.

Relative risk reduction was preserved, regardless of angiotensin-converting–enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) dose …

Reviewing Author

Kirsten E. Fleischmann, MD, MPH, FACC

Disclosures

Grant/Research SupportNational Institutes of Health

Leadership Positions in Professional SocietiesAmerican College of Cardiology/American Heart Association

Kirsten E. Fleischmann, MD, MPH, FACC

Disclosures

Grant/Research SupportNational Institutes of Health

Leadership Positions in Professional SocietiesAmerican College of Cardiology/American Heart Association

Empagliflozin for HFrEF — Post Hoc Analysis of EMPEROR-Reduced

Topics

Reviewing Author